Kardigan
About Kardigan
The startup specializes in matching cardiovascular disease drivers with treatment responders identified in clinical trials, utilizing advanced data analytics to enhance drug development processes. This approach ensures that patients gain access to targeted therapies that effectively address their specific heart health conditions.
<problem> Cardiovascular disease remains the leading cause of death globally, with significant unmet needs in effectively treating diverse patient populations and subtypes of disease. Current treatments often focus on symptom management rather than addressing the underlying disease mechanisms, resulting in suboptimal outcomes for many patients. </problem> <solution> Kardigan is a biopharmaceutical company focused on modernizing cardiovascular drug development through a personalized medicine approach. The company leverages a proprietary cardiac-specific R&D platform, termed "Cardiac Intelligence," to identify critical disease drivers and match them with treatment responders. By integrating cutting-edge discovery, translational research, and strategic in-licensing, Kardigan aims to develop a portfolio of disease-modifying medicines that target the underlying pathophysiology of cardiovascular disease. This approach enables effective patient segmentation and streamlined clinical trials, delivering novel therapies to patients who have the greatest potential to benefit. </solution> <features> - Proprietary Cardiac Intelligence R&D platform for deep understanding of drug mechanisms and patient responses - Portfolio of late-stage clinical candidates designed to target critical disease drivers - AI technology-enhanced clinical trials leveraging Prolaio's health technology expertise - Tech-enabled clinical trial enrichment capability to translate high-density data into insights - FDA-cleared software to increase statistical power, improve patient screening and compliance - Identification of patient subgroups and tracking of safety and efficacy signals with greater accuracy - Integration of AI-based tools and continuous real-world measurements to optimize clinical study design </features> <target_audience> Kardigan's primary target audience includes patients with cardiovascular diseases, particularly those with primary and secondary cardiomyopathies leading to heart failure, as well as clinical researchers and healthcare providers focused on cardiovascular medicine. </target_audience> <revenue_model> Kardigan is funded by a $300 million Series A financing round led by Perceptive Advisors, ARCH Venture Partners, and Sequoia Heritage. </revenue_model>
What does Kardigan do?
The startup specializes in matching cardiovascular disease drivers with treatment responders identified in clinical trials, utilizing advanced data analytics to enhance drug development processes. This approach ensures that patients gain access to targeted therapies that effectively address their specific heart health conditions.
Where is Kardigan located?
Kardigan is based in South San Francisco, United States.
When was Kardigan founded?
Kardigan was founded in 2023.
How much funding has Kardigan raised?
Kardigan has raised 300000000.
- Location
- South San Francisco, United States
- Founded
- 2023
- Funding
- 300000000
- Employees
- 57 employees
- Major Investors
- ARCH Venture Partners, Perceptive Advisors